Of these, tocilizumab/Actemra and sarilumab/Kevzara antibodies capable of binding to the interleukin-6 receptor (IL-6R) and promoted for therapy of rheumatoid arthritis can be repurposed for Covid-19 therapy. Here, IL6R is linked to rheumatoid arthritis.